Therapeutic Recombinant Murine Activated Protein C Attenuates Pulmonary Coagulopathy and Improves Survival in Murine Pneumococcal Pneumonia | Zendy

Marcel Schouten | Zendy; Cornelis van ‘t Veer | Zendy; Florry E. van den Boogaard | Zendy; Bruce Gerlitz | Zendy; Brian W. Grinnell | Zendy; Joris J. T. H. Roelofs | Zendy; Marcel Levi | Zendy; Tom van der Poll | Zendy

Open Access

Therapeutic Recombinant Murine Activated Protein C Attenuates Pulmonary Coagulopathy and Improves Survival in Murine Pneumococcal Pneumonia

Author(s) -

Marcel Schouten,

Cornelis van ‘t Veer,

Florry E. van den Boogaard,

Bruce Gerlitz,

Brian W. Grinnell,

Joris J. T. H. Roelofs,

Marcel Levi,

Tom van der Poll

Publication year - 2010

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/656787

Subject(s) - pneumococcal pneumonia , pneumonia , medicine , coagulopathy , sepsis , protein c , immunology , recombinant dna , streptococcus pneumoniae , antibiotics , coagulation , inflammation , microbiology and biotechnology , biology , biochemistry , gene

Recombinant human activated protein C (APC) improves survival of patients with severe sepsis; this beneficial effect is especially apparent in patients with pneumococcal pneumonia. The aim of this study was to determine the effect of APC treatment initiated after induction of pneumococcal pneumonia on pulmonary coagulation, inflammation, and survival, with or without concurrent antibiotic therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research